Skip to main content

ORIGINAL RESEARCH

Pathol. Oncol. Res., 07 September 2023

Active cancer as the main predictor of mortality for COVID-19 in oncology patients in a specialized center

Freddy Villanueva-Cotrina,
Freddy Villanueva-Cotrina1,2*Juan VelardeJuan Velarde3Ricardo Rodriguez,Ricardo Rodriguez1,4Alejandra BonillaAlejandra Bonilla5Marco LauraMarco Laura5Tania Saavedra,Tania Saavedra6,7Diana Portillo-Alvarez,Diana Portillo-Alvarez3,8Yovel Bustamante,Yovel Bustamante1,2Cesar FernandezCesar Fernandez1Marco Galvez-Nino,Marco Galvez-Nino7,9
  • 1Department of Pathology, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru
  • 2Academic Department of Medical Microbiology, Universidad Nacional Mayor de San Marcos, Lima, Peru
  • 3Department of Infectious Diseases, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru
  • 4Academic Department of Medical Technologist, Universidad Nacional Mayor de San Marcos, Lima, Peru
  • 5Department of Radiodiagnosis, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru
  • 6Department of Critical Care Medicine, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru
  • 7Professional School of Human Medicine, Universidad Privada San Juan Bautista, Lima, Peru
  • 8Professional School of Human Medicine, Universidad de Piura, Lima, Peru
  • 9Department of Medical Oncology, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru

Abstract
Introduction: The role of the type, stage and status of cancer in the outcome of COVID-19 remains unclear. Moreover, the characteristic pathological changes of severe COVID-19 reveled by laboratory and radiological findings are similar to those due to the development of cancer itself and antineoplastic therapies.

Objective: To identify potential predictors of mortality of COVID-19 in cancer patients.

Materials and methods: A retrospective and cross-sectional study was carried out in patients with clinical suspicion of COVID-19 who were confirmed for COVID-19 diagnosis by RT-PCR testing at the National Institute of Neoplastic Diseases between April and December 2020. Demographic, clinical, laboratory and radiological data were analyzed. Statistical analyses included area under the curve and univariate and multivariate logistic regression analyses.

Results: A total of 226 patients had clinical suspicion of COVID-19, the diagnosis was confirmed in 177 (78.3%), and 70/177 (39.5%) died. Age, active cancer, leukocyte count ≥12.8 × 109/L, urea ≥7.4 mmol/L, ferritin ≥1,640, lactate ≥2.0 mmol/L, and lung involvement ≥35% were found to be independent predictors of COVID-19 mortality.

Conclusion: Active cancer represents the main prognosis factor of death, while the role of cancer stage and type is unclear. Chest CT is a useful tool in the prognosis of death from COVID-19 in cancer patients. It is a challenge to establish the prognostic utility of laboratory markers as their altered values it could have either oncological or pandemic origins.

Introduction

COVID-19 disease leads to severe pneumonia, metabolic acidosis, coagulation dysfunction, multiple organ failure, and eventually, death [14]. Cancer patients usually have a compromised immune system with a higher risk of death in COVID-19 compared to those without cancer [58], but it is not clear if the type, stage and status of cancer play a role in the outcome of the disease.

COVID-19 diagnosis is based on clinical evaluation and confirmed by the detection of viral RNA in respiratory samples [9]. Furthermore, certain blood laboratory parameters and chest computed tomography (CT) findings could reveal characteristic pathological changes and the clinical course of COVID-19 in oncology patients. Altered levels of C-reactive protein (CRP), neutrophil and lymphocyte counts, ferritin, D-dimer, and lactate dehydrogenase [1012], as well as a high CO-RADS score and the presence of some abnormal chest CT findings have been associated with the presentation of severe complications of COVID-19 [13, 14].

However, malignant neoplasms lead to similar laboratory and radiological alteration findings due to pathological events in the development of cancer itself (acute renal failure, disseminated intravascular coagulation, impaired cellular immunity, organ failure, respiratory failure) [1521] and antineoplastic therapies (immunosuppression, hepatotoxicity) [22, 23]. Therefore, it is unknown whether these potential predictors are useful for detecting the clinical course of the disease in cancer patients.

We aimed to identify predictors of mortality of COVID-19 in cancer patients by the joint study of the clinical characteristics, laboratory and radiological findings, and their association with a higher risk of a fatal outcome.

Materials and methods

Study design and population

This retrospective and cross-sectional study was carried out in patients hospitalized at the Instituto Nacional de Enfermedades Neoplasicas (INEN) in Lima—Peru between April and December 2020. The study sample included patients who presented with a clinical suspicion of COVID-19 and were confirmed for COVID-19 diagnosis by RT-PCR testing. Patients with a clinical or radiological diagnosis of COVID-19 without a positive RT-PCR test were excluded. When patients had two positive results for COVID-19 by RT-PCR, only the first one was considered.

Clinical, laboratory, radiological and outcome data

Demographic, clinical, laboratory, radiological and outcomes data were collected blind from the medical records and the INEN informatic system. Blood sample tests and chest CT scans were performed within 24 h after sampling for the COVID-19 molecular diagnosis. While clinical outcome, mortality or survival, was considered until 30 days after the molecular study was performed. A specialist physician from the Department of Infectious Diseases evaluated the records of the clinical presentation, while two specialist physicians from the Department of Medical Oncology evaluated the stage and status of cancer in the patients. Two specialist physicians from the Department of Radiodiagnosis evaluated the chest CT images to determine the presence of abnormal findings, the percentage of affected lung, and the COVID-19 Reporting and Data System (CO-RADS) score classification system.

To determine the percentage of affected lung, each of the five lung lobes was scored visually on a scale from 0 to 5, (where 0 indicates no involvement; 1, less than 5%; 2, 5%–25%; 3, 26%–49%; 4, 50%–75%; and 5, more than 75%). The total CT score was the sum of the individual lobar scores and ranged from 0 (no involvement) to 25 (maximum involvement) [24]. The CO-RADS system assessed lung damage on a chest CT to predict the likelihood of COVID-19 pneumonia using a scale from 1 (very low) to 5 (very high). A high CO-RADS score indicates a high probability of COVID-19; thus, the grouped frequency of COVID-19 in categories 1, 2, 3, 4 and 5 corresponds to 8.8%, 11.1%, 24.6%, 61.9% and 89.6% involvement, respectively) [25].

Definitions

Cases with clinical suspicion of COVID-19: Patients present any of the following symptoms: fever, cough, fatigue, headache, dyspnea, myalgia, diarrhea, tachypnea, chest pain, anosmia, and ageusia.

Confirmed cases of COVID-19: Patients who tested positive for COVID-19 in the molecular study (PCR-RT) from nasopharyngeal swab samples.

Active cancer: Presence of cancer progression or recurrence after treatment.

Advanced cancer: Presence of distant metastatic disease.

Clinical scenario: Clinical presentation of patients according to WHO [26].

Compliance with ethics guidelines

All the cases in this study were part of the medical care routine of the INEN. No informed consent from any patient was obtained since this study used laboratory test registers, radiological reports of the INEN informatic system, and patient medical records in obtaining data which were used protecting the identity of the patients. The protocol was presented to the Research Committee of the INEN and approved for its implementation with designated protocol number INEN 20-49.

Statistical analysis

Categorical variables were analyzed using the chi-squared or Fisher’s exact test, as appropriate, and presented as frequencies and percentages. Quantitative variables were described as means and standard deviation or medians and interquartile ranges, depending on the distribution of the data. Quantitative variables were evaluated using the Student’s t-test when there was a normal distribution of the data and, when not, using the Mann-Whitney U test. Receiver operating characteristic (ROC) curve analysis provided the sensitivity and specificity of the laboratory tests and radiological findings for the prediction of mortality from COVID-19. In addition, it allowed us to obtain the best cut-off points for the categorization of these variables according to the Youden Index. Finally, the univariate and multivariate regression analyses were performed to obtain the odds ratio (OR) as a measure of association between the variables and the mortality prediction of COVID-19, considering only the associated variables in the bivariate analysis for building the final multivariate model. For all analyses, statistical significance was set at p < 0.05. All analyses were performed using Stata version 14.0.

Results

During the study period, 226 patients had clinical suspicion of COVID-19 from which 177 (78.3%) were confirmed. Of the 177 positive cases of COVID-19, most patients were between 16 and 59 years old (84, 47.5%), male (96, 54.2%), had solid tumors (95, 53.7%), non-advanced stage (104, 58.8%) and active status cancer (111, 62.7%). Of these, 70 (39.5%) died, one-third of the deaths of patients with COVID-19 occurred within the first 5 days (24/70, 34.4%), and the vast majority (52/70, 74.3%) had died by day 15 after molecular study sampling.

Prediction of COVID-19 mortality

The deceased patients were older (62.5 vs. 42.0; p ≤ 0.001), had severe-critical clinical scenario (56.6% vs. 26.7%; p ≤ 0.001) and active cancer (48.7% vs. 24.2%; p = 0.001) (Table 1).

TABLE 1
www.frontiersin.org

TABLE 1. Demographic, clinical and oncological characteristics of 177 cases of cancer patients with COVID-19 according to mortality.

Likewise, these patients had a higher leukocyte count (10.4×109/L vs. 6.6×109/L; p = 0.001), neutrophil count (8.63 × 109/L vs. 5.26 × 109/L; p = 0.001), RNL (15.1 vs. 7.8; p = 0.001), D-dimer (2,136 ng/mL vs. 1,034 ng/mL; p = 0.002), LDH (329 U/L vs. 249 U/L; p = 0.004), urea (6.0 mmol/L vs. 4.0 mmol/L; p ≤ 0.001), creatinine (56 umol/L vs. 48 umol/L; p = 0.018, lactate (1.9 mmol/L vs. 1.3 mmol/L; p ≤ 0.001), lung involvement (40% vs. 20%; p ≤ 0.001) and crazy paving (56.3% vs. 32.3%) (Table 2).

TABLE 2
www.frontiersin.org

TABLE 2. Comparison of laboratory tests and CT findings in 177 cancer patients with COVID-19 according to mortality.

The evaluation of the area under the curve showed that urea ≥7.4 mmol/L had the highest ability to predict death, with AUC 0.751 (S = 40.63% and E = 91.75%), followed by lactate ≥2.0 mmol/L, AUC 0.686 (S = 47.54% and E = 86.49%) and lung involvement ≥35%, AUC 0.662 (S = 59.70%, E = 66.67%) (Table 3).

TABLE 3
www.frontiersin.org

TABLE 3. Prognostic capacity of death of laboratory tests and CT findings in cancer patients with COVID-19.

Finally, in the bivariate regression analysis, a higher probability of death was found in patients over 60 years of age (OR 6.72; p = 0.005) compared to those under 16 years of age and with increasing age per year (OR 1.04; p ≤ 0.001), severe-critical clinical scenario (OR 3.57; p ≤ 0.001), active cancer (OR 2.96; p = 0.002), advanced cancer (OR 1.61; p = 0.082), leukocyte count ≥12.8 × 109/L (OR 2.92; p = 0.003), neutrophil count ≥7.51 × 109/L (OR 3.55; p ≤ 0.001), RNL ≥14.5 (OR 3.00; p = 0.001), fibrinogen ≥9.39 g/L (OR 9.94; p = 0.035), D-dimer ≥1,345 ng/mL (OR 2.57; p = 0.003), LDH ≥329 U/L (OR 2.54; p = 0.004), urea ≥7.4 mmol/L (OR 7.31; p ≤ 0.001), creatinine ≥71 umol/L (OR 3.77; p = 0.001), ferritin ≥1,640 (OR 3.09; p = 0.017), lactate ≥2.0 mmol/L (OR 6.86; p ≤ 0.001), lung involvement ≥35% (OR 3.27; p ≤ 0.001), crazy paving (OR 2.58; p = 0.001) and vessel thickening (OR 1.91; p = 0.011), and a lower probability in patients with oxygen saturation ≥86.9% (OR 0.45; p = 0.029). Multivariate analysis found an association with a higher probability of death with increasing age per year (OR 1.04; p = 0.001), active cancer (OR 7.56; p≤0.001), leukocyte count ≥12.8 × 109/L (OR 3.00; p = 0.022), urea ≥7.4 mmol/L (OR 3.20; p = 0.034), ferritin ≥1,640 (OR 7.22; p = 0.005), lactate ≥2.0 mmol/L (OR 4.79; p = 0.002) and lung involvement ≥35% (OR 4.34; p = 0.002) (Table 4).

TABLE 4
www.frontiersin.org

TABLE 4. Factors associated with mortality in cancer patients with COVID-19.

Discussion

The mortality rate in our population during the first wave of the pandemic was higher than that found in cancer patients with COVID-19, whose mortality rates were highly variable [27]. It could be related to underlying clinical conditions. We emphasize that our study was conducted only in hospitalized patients, most of whom had active cancer. In addition, numerous deaths occurred shortly after the diagnosis of COVID-19, which shows delayed medical care resulting from the impact of the pandemic on hospital capacity in our country [28]. The high in-hospital mortality rate was related to the critical baseline condition of the patients.

Oncological characteristics could play a role in the outcome of COVID-19 in our population. The strong association between active cancer stage and an increased risk of death coincides with the findings of some studies [10, 2932]. Active cancer leads to prothrombotic and proinflammatory conditions that concur with alterations in the immune system due to the development of cancer and antineoplastic treatments [33, 34]. Moreover, SARS-CoV-2 infection results in immune alterations and thrombotic events. Therefore, this could lead to an unfavorable prognosis in patients with cancer and COVID-19 [35, 36]. Advanced or metastatic cancer has been associated with an increased risk of death [37]. In our study, we observed this association, although it was not significant. Findings in this regard are contradictory; some studies have found it to be a risk factor for death in COVID-19 [10, 11, 27, 32], while others have not [12, 3840]. In contrast, the non-association between the type of cancer, solid tumor or hematological neoplasm, and the probability of death in COVID-19 patients coincides with several studies [1012, 27, 3032, 39].

Active cancer represents the main vulnerability of cancer patients in the pandemic, otherwise there is still a need to better understand the possible role of the cancer stage and the type of neoplasia in the outcome of COVID-19.

Mortality in cancer patients with COVID-19 increases with each year of age. Older age leads to a deficiency in the immune response, resulting in a higher risk of death in COVID-19 patients [41]. The strength and direction of the association between age and COVID-19 mortality have been consistently found across multiple studies [1012, 27, 2932, 3840].

The alteration of some laboratory parameters could be a manifestation of the pathophysiology of the disease, but it could also be due to cancer itself.

The high serum concentrations of lactate and, in particular, of ferritin could be the result of a sustained and hyperactive inflammatory response in the COVID-19 patient [3]. Increasing concentrations of serum ferritin, according to the proposed cut-off values, were strongly associated with the mortality of COVID-19 in our population. Serum ferritin levels increase because of cell damage and severe uncontrolled inflammatory conditions [41, 42] including malignant diseases and their progression [43, 44]. The threshold value evaluated (≥1,640 ng/mL) represent a significant increase in serum concentration and correlate with a hyperinflammatory state and a severe clinical course in COVID-19 [45, 46]. Moreover, the increase in serum ferritin has been associated with the severity and mortality of COVID-19 in oncology population, even with lower threshold values [11]. In contrast, a slight increase in serum lactate was associated with mortality. Lactate is a metabolite that is increased in the blood during tissue hypoxia and hypermetabolism, which results in tissue damage and organ failure [47, 48]. Hyperlactatemia (lactate >2.0 mmol/L) is associated with septic shock and mortality in cancer patients with a high incidence of sepsis-related morbidity and mortality [49]. Also, increased values of this analyte in blood, similar to the threshold evaluated in our study (≥2.0 mmol/L), have been found to be a predictor of mortality for COVID-19 in cancer patients, although with a higher threshold value [11]. Serum urea level was another biochemical marker of mortality in the present study. Measurement of uremia is routinely performed to evaluate renal function and its increase as an indicator of renal insufficiency [50, 51]. Although renal insufficiency is a frequent clinical condition in patients with cancer [16, 18], with the consequent increase in serum urea, it is also an important sequela of COVID-19 [52, 53]. The study of blood urea had a good prognostic capacity and association with mortality, although with a slightly higher threshold value (≥7.4 mmol/L). This could indicate the beginning of the manifestation of kidney damage and could also be due to the presence of renal comorbidity in some patients. Increased serum levels of urea (in the form of BUN) have been associated with higher mortality for COVID-19 in cancer patients [54]. Monitoring the evolution of uremia and the study of other complementary tests could contribute to a better understanding of this prognostic factor.

In the hematological study, the leukocyte count seems to be an unspecified marker. An increased leukocyte count represents an inflammatory state resulting from the innate immune response to infection [55, 56]. Likewise, leukocytes are also increased in malignant neoplasms due to the close relationship between the development and progression of cancer and a state of systemic inflammation [5759]. The increased leukocyte count would indicate a severe inflammatory reaction as a consequence of COVID-19 in cancer patients, even with lower threshold values [12]. However, this finding must be evaluated by considering the oncological context in which many neoplasms frequently maintain leukocytosis, as a subclinical proinflammatory state. In contrast, the total leukocyte count may be affected by the toxicity of antineoplastic therapy in patients under treatment [60, 61]. Contrary to the well-known association found between coagulation markers and COVID-19, we observed no such association. The values of D-dimer, fibrinogen and platelets are frequently altered due to the complication of cancer and its treatment, especially when the disease is active [62, 63].

Although we found some laboratory markers associated with mortality, establishing the prognostic utility of these parameters requires considering that their increased concentration may be due to the underlying neoplasm and/or to the manifestation of the severity of COVID-19.

Chest CT showed a prognostic association with death in COVID-19 through the evaluation of the percentage of affected lungs. To the best of our knowledge there is no association studies between chest CT score system and COVID-19 in oncology patients. However, chest CT can be useful in the study of COVID-19 in cancer patients in which it can show atypical images with few or solitary abnormal findings; therefore, rare or subtle patterns can characterize SARS-CoV-2 infection [13].

CT scoring could help to stratify patient risk and predict short-term outcome in COVID-19 pneumonia [64]. The expression of global pulmonary involvement, regardless of the alteration type, allows us to predict clinical evolution [65], since with the semiquantitative scoring system to estimate lung involvement, all the abnormalities present in the CT are taken into account based on the affected area. Lung involvement score on chest CT in the general population associated with mortality were ≥15 (lung involvement ≥60%) [66, 67] and ≥12.5 [68]. However, in our study, a lung CT score of ≥8.75 (lung involvement ≥35%) was associated with a higher probability of death, which could have been due to limited immune function, especially in patients with hematological neoplasms receiving antineoplastic treatment and with leukopenia [13]. The extent of lung involvement observed on CT, even at a low percentage, could help identify cancer patients at a high risk of death.

Although, there is limited data on chest CT for the diagnosis of COVID-19 pneumonia with a focus on cancer populations [14], in evaluating multiple and non-specific findings, chest CT is a useful tool in the prognosis of death from COVID-19 in cancer patients.

In summary, our clinical study attempted to clarify the role of cancer in the fatality of COVID-19 infection. We found several serum markers and imaging patterns of mortality, but mainly we identified active cancer, cancer progression or its recurrence after treatment, as a critical variable. Our findings derive from a comprehensive clinical, laboratory, and imaging analysis, highlighting the complex interplay of oncologic features and the pathophysiology of COVID-19 to predict the fatal outcome of the disease.

Limitations

Our study had some limitations that do not invalidate the results; on the contrary, they lead to the proposal of further evaluations to overcome them. First, the small size of the cohort, which probably prohibited to clarify or detect associations due to insufficient statistical power, as we only had access to the complete information of patients with COVID-19 for the study period of time. Second, recognized markers were not evaluated in the COVID-19 study, such as interleukin 6 and procalcitonin, which were not available or were economically unfeasible for developing countries such as ours. Third, neoplastic treatment, which can influence the total leukocyte count, was not analyzed in the study, although the toxic effect of this therapy occurs in all cell types. Finally, cases that had incomplete information could have generated some bias in the results, although the missing data were expected to be undifferentiated for the groups analyzed.

Conclusions

• Active cancer represents the main prognosis factor of death, while the role of cancer stage and type is unclear.

• Chest CT is a useful tool in the prognosis of death from COVID-19 in cancer patients.

• It is a challenge to establish the prognostic utility of laboratory markers as the alteration of their values can have either oncological or pandemic origins.

• Clinical, laboratory and radiological correlations can help improve the prognosis of death in cancer patients with pulmonary involvement due to COVID-19.

Data availability statement

The raw data supporting the conclusion of this article will be made available by the authors, without undue reservation.

Ethics statement

All the cases in this study were part of the medical care routine of the INEN. No informed consent from any patient was obtained since this study used laboratory test registers and patient medical records in obtaining data which were used protecting the identity of the patients. The protocol was presented to the Research Committee of the INEN and approved for its implementation with designated protocol number INEN 20-49.

Author contributions

FV-C and JV conceived and designed the study. JV, RR, AB, ML, TS, DP, YB, and MG acquired data. FV-C, RR, YB, CF, and MG analyzed the data, and FV-C, RR, AB, ML, TS, DP, YB, and MG-N wrote manuscript. All authors contributed to the article and approved the submitted version.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

1. Guan, WJ, Niyi, Z, Hu, Y, Liang, WH, Ou, CQ, He, JX, et al. Clinical characteristics of coronavirus disease 2019 in China. New Engl J Med (2020) 382(18):1708–20. doi:10.1056/nejmoa2002032

PubMed Abstract | CrossRef Full Text | Google Scholar

2. Shi, M, Chen, L, Yang, Y, Zhang, J, Xu, J, Xu, G, et al. Analysis of clinical features and outcomes of 161 patients with severe and critical COVID-19: a multicenter descriptive study. J Clin Lab Anal (2020) 34(9):e23415. doi:10.1002/jcla.23415

PubMed Abstract | CrossRef Full Text | Google Scholar

3. Wang, D, Hu, B, Hu, C, Zhu, F, Liu, X, Zhang, J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA - J Am Med Assoc (2020) 323(11):1061–9. doi:10.1001/jama.2020.1585

CrossRef Full Text | Google Scholar

4. Yakovenko, OK, Khanin, OG, Lotysh, VV, and Gryf, SL. Clinical features of severe COVID-19 with lethal outcome in volyn region residents. Ukrainian Pulmonology J (2021) 29(2):16–24. doi:10.31215/2306-4927-2021-29-2-16-24

CrossRef Full Text | Google Scholar

5. Yang, L, Chai, P, Yu, J, and Fan, X. Effects of cancer on patients with COVID-19: a systematic review and meta-analysis of 63,019 participants. Cancer Biol Med (2021) 18:298–307. doi:10.20892/j.issn.2095-3941.2020.0559

PubMed Abstract | CrossRef Full Text | Google Scholar

6. Bernard, A, Cottenet, J, Bonniaud, P, Piroth, L, Arveux, P, Tubert-Bitter, P, et al. Comparison of cancer patients to non-cancer patients among COVID-19 inpatients at a national level. Cancers (Basel) (2021) 13(6):1436–15. doi:10.3390/cancers13061436

PubMed Abstract | CrossRef Full Text | Google Scholar

7. Rajeev Nadkarni, A, Vijayakumaran, SC, Gupta, S, and Divatia, JV. Mortality in cancer patients with COVID-19 who are admitted to an ICU or who have severe COVID-19: a systematic review and meta-analysis. JCO Glob Oncol (2021) 7:1286–305. doi:10.1200/go.21.00072

PubMed Abstract | CrossRef Full Text | Google Scholar

8. Wang, L, Sun, Y, Yuan, Y, Mei, Q, and Yuan, X. Clinical challenges in cancer patients with COVID-19: aging, immunosuppression, and comorbidities. Aging (2020) 12:24462–74. doi:10.18632/aging.104205

PubMed Abstract | CrossRef Full Text | Google Scholar

9. Health Organization, W. Guideline clinical management of COVID-19 patients: living guideline (2021). Available from: http://apps.who.int/bookorders (Accessed November 23, 2021).

Google Scholar

10. Nader Marta, G, Colombo Bonadio, R, Nicole Encinas Sejas, O, Watarai, G, Mathias Machado, MC, Teixeira Frasson, L, et al. Outcomes and prognostic factors in a large cohort of hospitalized cancer patients with COVID-19. JCO Glob Oncol (2021) 7:1084–92. doi:10.1200/GO.21.00087

PubMed Abstract | CrossRef Full Text | Google Scholar

11. Mina, A, Galvez, C, Karmali, R, Mulcahy, M, Mi, X, Kocherginsky, M, et al. Outcomes of cancer patients with COVID-19 in a hospital system in the Chicago metropolitan area. Cancers (Basel) (2022) 14(9):2209. doi:10.3390/cancers14092209

PubMed Abstract | CrossRef Full Text | Google Scholar

12. Benderra, MA, Aparicio, A, Leblanc, J, Wassermann, D, Kempf, E, Galula, G, et al. Clinical characteristics, care trajectories and mortality rate of SARS-CoV-2 infected cancer patients: a multicenter cohort study. Cancers (Basel). (2021) 13(19):4749. doi:10.3390/cancers13194749

PubMed Abstract | CrossRef Full Text | Google Scholar

13. Katal, S, Aghaghazvini, L, and Gholamrezanezhad, A. Chest-CT findings of COVID-19 in patients with pre-existing malignancies; a pictorial review. Clin Imaging (2020) 67:121–9. doi:10.1016/j.clinimag.2020.06.004

PubMed Abstract | CrossRef Full Text | Google Scholar

14. Bourdoncle, S, Eche, T, McGale, J, Yiu, K, Partouche, E, Yeh, R, et al. Investigating of the role of CT scan for cancer patients during the first wave of COVID-19 pandemic. Res Diagn Interv Imaging (2022) 1:100004. doi:10.1016/j.redii.2022.100004

PubMed Abstract | CrossRef Full Text | Google Scholar

15. Levi, M. Disseminated intravascular coagulation in cancer patients. Best Pract Res Clin Haematol (2009) 22:129–36. doi:10.1016/j.beha.2008.12.005

PubMed Abstract | CrossRef Full Text | Google Scholar

16. Humphreys, BD, Soiffer, RJ, and Magee, CC. Renal failure associated with cancer and its treatment: an update. J Am Soc Nephrol (2005) 16:151–61. doi:10.1681/ASN.2004100843

PubMed Abstract | CrossRef Full Text | Google Scholar

17. Levi, M. Disseminated intravascular coagulation in cancer: an update. Semin Thromb Hemost (2019) 45(4):342–7. doi:10.1055/s-0039-1687890

PubMed Abstract | CrossRef Full Text | Google Scholar

18. Lameire, NH, Flombaum, CD, Moreau, D, and Ronco, C. Acute renal failure in cancer patients. Ann Med (2005) 37:13–25. doi:10.1080/07853890510007205

PubMed Abstract | CrossRef Full Text | Google Scholar

19. Kavanaugh, DY, and Carbone, DP. Immunologic dysfunction in cancer. Oncology (Williston Park) (1996) 10:927–51. doi:10.1016/s0889-8588(05)70376-2

PubMed Abstract | CrossRef Full Text | Google Scholar

20. Cedervall, J, Zhang, Y, and Olsson, AK. Tumor-induced NETosis as a risk factor for metastasis and organ failure. Cancer Res (2016) 76:4311–5. doi:10.1158/0008-5472.CAN-15-3051

PubMed Abstract | CrossRef Full Text | Google Scholar

21. Nava, S, and Cuomo, AM. Acute respiratory failure in the cancer patient: the role of non-invasive mechanical ventilation. Crit Rev Oncology/Hematology (2004) 51:91–103. doi:10.1016/j.critrevonc.2004.04.004

PubMed Abstract | CrossRef Full Text | Google Scholar

22. Vial, T, and Descotes, J. Immunosuppressive drugs and cancer. Toxicology (2003) 185(3):229–40. doi:10.1016/s0300-483x(02)00612-1

PubMed Abstract | CrossRef Full Text | Google Scholar

23. Ngo, D, Jia, JB, Green, CS, Gulati, AT, and Lall, C. Cancer therapy related complications in the liver, pancreas, and biliary system: an imaging perspective. Insight Imaging (2015) 6:665–77. doi:10.1007/s13244-015-0436-7

PubMed Abstract | CrossRef Full Text | Google Scholar

24. Pan, F, Ye, T, Sun, P, Gui, S, Liang, B, Li, L, et al. Time course of lung changes at chest CT during recovery from Coronavirus disease 2019 (COVID-19). Radiology (2020) 295(3):715–21. doi:10.1148/radiol.2020200370

PubMed Abstract | CrossRef Full Text | Google Scholar

25. Prokop, M, van Everdingen, W, van Rees Vellinga, T, van Ufford, HQ, Stöger, L, Beenen, L, et al. CO-RADS: a categorical CT assessment scheme for patients suspected of having COVID-19-definition and evaluation. Radiology (2020) 296(2):E97–104. doi:10.1148/radiol.2020201473

PubMed Abstract | CrossRef Full Text | Google Scholar

26. World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: interim guidance 2 1. In: Triage: early recognition of patients with SARI associated with nCoV infection (2020). Available from: https://apps.who.int/iris/bitstream/handle/10665/331446/WHO-2019-nCoV-clinical-2020.4-eng.pdf?sequence=1&isAllowed=y (Accessed March 13, 2020).

Google Scholar

27. Ferrari, BL, Carlos, , , Ferreira, G, Menezes, M, de Marchi, P, Canedo, J, et al. Determinants of COVID-19 mortality in patients with cancer from a community oncology practice in Brazil. JCO Glob Oncol (2021) 7:46–55. doi:10.1200/GO.20.00444

PubMed Abstract | CrossRef Full Text | Google Scholar

28. Meza Riquelme, MJS, Condori Pereyra, AR, and Encalada Carbajal, DA. Análisis de políticas públicas en el Perú ante la crisis derivada de la COVID-19. Semestre Económico (2020) 23(55):113–38. doi:10.22395/seec.v23n55a5

CrossRef Full Text | Google Scholar

29. Zorzi, M, Guzzinati, S, Avossa, F, Fedeli, U, Calcinotto, A, and Rugge, M. SARS-CoV-2 infection in cancer patients: a population-based study. Front Oncol (2021) 11:730131. doi:10.3389/fonc.2021.730131

PubMed Abstract | CrossRef Full Text | Google Scholar

30. Kuderer, NM, Choueiri, TK, Shah, DP, Shyr, Y, Rubinstein, SM, Rivera, DR, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. The Lancet (2020) 395(10241):1907–18. doi:10.1016/S0140-6736(20)31187-9

PubMed Abstract | CrossRef Full Text | Google Scholar

31. Borno, HT, Kim, MO, Hong, JC, Yousefi, S, Lin, A, Tolstykh, I, et al. COVID-19 outcomes among patients with cancer: observations from the university of California cancer consortium COVID-19 project outcomes registry. Oncologist (2022) 27(5):398–406. doi:10.1093/oncolo/oyac038

PubMed Abstract | CrossRef Full Text | Google Scholar

32. Pinato, DJ, Scotti, L, Gennari, A, Colomba-Blameble, E, Dolly, S, Loizidou, A, et al. Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study. Eur J Cancer (2021) 150:190–202. doi:10.1016/j.ejca.2021.03.035

PubMed Abstract | CrossRef Full Text | Google Scholar

33. Schreiber, RD, Old, LJ, and Smyth, MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science (2011) 331(6024):1565–70. doi:10.1126/science.1203486

PubMed Abstract | CrossRef Full Text | Google Scholar

34. Khorana, AA, Mackman, N, Falanga, A, Pabinger, I, Noble, S, Ageno, W, et al. Cancer-associated venous thromboembolism. Nat Rev Dis Primers (2022) 8(1):11–8. doi:10.1038/s41572-022-00336-y

PubMed Abstract | CrossRef Full Text | Google Scholar

35. Connors, JM, and Levy, JH. Thromboinflammation and the hypercoagulability of COVID-19. J Thromb Haemost (2020) 18:1559–61. doi:10.1111/jth.14849

PubMed Abstract | CrossRef Full Text | Google Scholar

36. Mangalmurti, N, and Hunter, CA. Cytokine storms understanding COVID-19. Immunity (2020) 53(1):19–25. doi:10.1016/j.immuni.2020.06.017

PubMed Abstract | CrossRef Full Text | Google Scholar

37. Owusuaa, C, Dijkland, SA, Nieboer, D, van der Heide, A, and van der Rijt, CCD. Predictors of mortality in patients with advanced cancer—a systematic review and meta-analysis. Cancers (2022) 14:328. doi:10.3390/cancers14020328

PubMed Abstract | CrossRef Full Text | Google Scholar

38. Ullgren, H, Camuto, A, Rosas, S, Pahnke, S, Ginman, B, Enblad, G, et al. Clinical characteristics and factors associated with COVID-19-related death and morbidity among hospitalized patients with cancer: a Swedish cohort study. Acta Oncologica (2021) 60(11):1459–65. doi:10.1080/0284186X.2021.1958005

PubMed Abstract | CrossRef Full Text | Google Scholar

39. Liu, Y, Lu, H, Wang, W, Liu, Q, and Zhu, C. Clinical risk factors for mortality in patients with cancer and COVID-19: a systematic review and meta-analysis of recent observational studies. Expert Rev Anticancer Ther (2021) 21(1):107–19. doi:10.1080/14737140.2021.1837628

PubMed Abstract | CrossRef Full Text | Google Scholar

40. Fattore, GL, Olivos, NSA, Olalla, JEC, Gomez, L, Marucco, AF, and Mena, MPR. Mortality in patients with cancer and SARS-CoV-2 infection: results from the argentinean network of hospital-based cancer registries. Cancer Epidemiol (2022) 79:102200. doi:10.1016/j.canep.2022.102200

PubMed Abstract | CrossRef Full Text | Google Scholar

41. Jergović, M, Coplen, CP, Uhrlaub, JL, and Nikolich-Žugich, J. Immune response to COVID-19 in older adults. J Heart Lung Transplant (2021) 40(10):1082–9. doi:10.1016/j.healun.2021.04.017

PubMed Abstract | CrossRef Full Text | Google Scholar

42. Kernan, KF, and Carcillo, JA. Hyperferritinemia and inflammation. Int Immunol (2017) 29(9):401–9. doi:10.1093/intimm/dxx031

PubMed Abstract | CrossRef Full Text | Google Scholar

43. Matzner, Y, Konijn, AM, and Hershko, C. Serum ferritin in hematologic malignancies. Am J Hematol (1980) 9:13–22. doi:10.1002/ajh.2830090103

PubMed Abstract | CrossRef Full Text | Google Scholar

44. Aulbert, E, and Steffens, O. Ferritin im serum-ein «tumormarker» bei malignen lymphomen? Oncology Research and Treatment (1990) 13(2):102–8. doi:10.1159/000216735

CrossRef Full Text | Google Scholar

45. Qeadan, F, Tingey, B, Gu, LY, Packard, AH, Erdei, E, and Saeed, AI. Prognostic values of serum ferritin and d-dimer trajectory in patients with covid-19. Viruses (2021) 13(3):419. doi:10.3390/v13030419

PubMed Abstract | CrossRef Full Text | Google Scholar

46. Depalma, RG, Hayes, VW, and O’Leary, TJ. Optimal serum ferritin level range: iron status measure and inflammatory biomarker. Metallomics (2021) 13(6):mfab030. doi:10.1093/mtomcs/mfab030

PubMed Abstract | CrossRef Full Text | Google Scholar

47. Bakker, J, Gris, P, Coffernils, M, Kahn, RJ, and Vincent, JL. Serial blood lactate levels can predict the development of multiple organ failure following septic shock. Am J Surg (1996) 171:221–6. doi:10.1016/S0002-9610(97)89552-9

PubMed Abstract | CrossRef Full Text | Google Scholar

48. Bakker, J, and Vincent, JL. The oxygen supply dependency phenomenon is associated with increased blood lactate levels. J Crit Care (1991) 6:152–9. doi:10.1016/0883-9441(91)90006-f

CrossRef Full Text | Google Scholar

49. Nazer, LH, Rimawi, D, and Hawari, FI. Evaluating the predictive value of lactate in patients with cancer having septic shock. J Intensive Care Med (2020) 35(8):789–96. doi:10.1177/0885066618788821

PubMed Abstract | CrossRef Full Text | Google Scholar

50. Bagshaw, SM, and Gibney, RTN. Conventional markers of kidney function. Crit Care Med (2008) 36:S152–8. doi:10.1097/CCM.0b013e318168c613

PubMed Abstract | CrossRef Full Text | Google Scholar

51. Stevens, LA, and Levey, AS. Measurement of kidney function. Med Clin North America (2005) 89:457–73. doi:10.1016/j.mcna.2004.11.009

CrossRef Full Text | Google Scholar

52. Peleg, Y, Kudose, S, D’Agati, V, Siddall, E, Ahmad, S, Nickolas, T, et al. Acute kidney injury due to collapsing glomerulopathy following COVID-19 infection. Kidney Int Rep (2020) 5(6):940–5. doi:10.1016/j.ekir.2020.04.017

PubMed Abstract | CrossRef Full Text | Google Scholar

53. Chueh, TI, Zheng, CM, Hou, YC, and Lu, KC. Novel evidence of acute kidney injury in COVID-19. J Clin Med (2020) 9(11):3547. doi:10.3390/jcm9113547

PubMed Abstract | CrossRef Full Text | Google Scholar

54. Nath, SS, Yadav, NU, Derkach, A, Perez-Johnston, R, Tachiki, L, Maguire, K, et al. Outcomes of patients with COVID-19 from a specialized cancer care emergency room. Cancer Invest (2022) 40(1):17–25. doi:10.1080/07357907.2021.1985134

PubMed Abstract | CrossRef Full Text | Google Scholar

55. Williams Donaldson, V. A clinical study of visualization on depressed white blood cell count in medical patient. Appl Psychophysiology Biofeedback (2000) 25(2):117–28. doi:10.1023/a:1009518925859

PubMed Abstract | CrossRef Full Text | Google Scholar

56. Kolaczkowska, E, and Kubes, P. Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol (2013) 13:159–75. doi:10.1038/nri3399

PubMed Abstract | CrossRef Full Text | Google Scholar

57. Balkwill, F, Charles, KA, and Mantovani, A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell (2005) 7:211–7. doi:10.1016/j.ccr.2005.02.013

PubMed Abstract | CrossRef Full Text | Google Scholar

58. Coussens, LM, and Werb, Z. Inflammation and cancer. Nature (2002) 420(6917):860–867.doi:10.1038/nature01322

PubMed Abstract | CrossRef Full Text | Google Scholar

59. Mantovani, A, Allavena, P, Sica, A, and Balkwill, F. Cancer-related inflammation. Nature (2008) 454:436–44. doi:10.1038/nature07205

PubMed Abstract | CrossRef Full Text | Google Scholar

60. Shitara, K, Matsuo, K, Oze, I, Mizota, A, Kondo, C, Nomura, M, et al. Meta-analysis of neutropenia or leukopenia as a prognostic factor in patients with malignant disease undergoing chemotherapy. Cancer Chemother Pharmacol (2011) 68(2):301–7. doi:10.1007/s00280-010-1487-6

PubMed Abstract | CrossRef Full Text | Google Scholar

61. Lowenthal, RM, and Eaton, K. Toxicity of chemotherapy. Hematology/Oncology Clinics (1996) 10(4):967–90. doi:10.1016/s0889-8588(05)70378-6

CrossRef Full Text | Google Scholar

62. Kvolik, S, Jukic, M, Matijevic, M, Marjanovic, K, and Glavas-Obrovac, L. An overview of coagulation disorders in cancer patients. Surg Oncol (2010) 19:e33–46. doi:10.1016/j.suronc.2009.03.008

PubMed Abstract | CrossRef Full Text | Google Scholar

63. de Cicco, M. The prothrombotic state in cancer: pathogenic mechanisms. Crit Rev Oncology/Hematology (2004) 50:187–96. doi:10.1016/j.critrevonc.2003.10.003

CrossRef Full Text | Google Scholar

64. Francone, M, Iafrate, F, Masci, GM, Coco, S, Cilia, F, Manganaro, L, et al. Chest CT score in COVID-19 patients: correlation with disease severity and short-term prognosis. Eur Radiol (2020) 30(12):6808–17. doi:10.1007/s00330-020-07033-y

PubMed Abstract | CrossRef Full Text | Google Scholar

65. Angeli, E, Dalto, S, Marchese, S, Setti, L, Bonacina, M, Galli, F, et al. Prognostic value of CT integrated with clinical and laboratory data during the first peak of the COVID-19 pandemic in northern Italy: a nomogram to predict unfavorable outcome. Eur J Radiol (2021) 137:109612. doi:10.1016/j.ejrad.2021.109612

PubMed Abstract | CrossRef Full Text | Google Scholar

66. Bayrak, V, Şentürk Durukan, N, Demirer Aydemir, F, Ergan, B, Gezer, NS, Eren Kutsoylu, OÖ, et al. Risk factors associated with mortality in ıntensive care COVID-19 patients: the importance of chest CT score and intubation timing as risk factors. Turk J Med Sci (2021) 51(4):1665–74. doi:10.3906/sag-2101-89

PubMed Abstract | CrossRef Full Text | Google Scholar

67. Li, K, Li, K, Chen, D, Chen, D, Chen, S, Chen, S, et al. Predictors of fatality including radiographic findings in adults with COVID-19. Respir Res (2020) 21(1):146. doi:10.1186/s12931-020-01411-2

PubMed Abstract | CrossRef Full Text | Google Scholar

68. Hajiahmadi, S, Shayganfar, A, Janghorbani, M, Esfahani, MM, Mahnam, M, Bakhtiarvand, N, et al. Chest computed tomography severity score to predict adverse outcomes of patients with COVID-19. Infect Chemother (2021) 53:308–18. doi:10.3947/ic.2021.0024

PubMed Abstract | CrossRef Full Text | Google Scholar

Keywords: SARS-CoV-2, imaging study, biomarkers, death prognosis, active cancer

Citation: Villanueva-Cotrina F, Velarde J, Rodriguez R, Bonilla A, Laura M, Saavedra T, Portillo-Alvarez D, Bustamante Y, Fernandez C and Galvez-Nino M (2023) Active cancer as the main predictor of mortality for COVID-19 in oncology patients in a specialized center. Pathol. Oncol. Res. 29:1611236. doi: 10.3389/pore.2023.1611236

Received: 10 April 2023; Accepted: 11 August 2023;
Published: 07 September 2023.

Edited by:

Anna Sebestyén, Semmelweis University, Hungary

Copyright © 2023 Villanueva-Cotrina, Velarde, Rodriguez, Bonilla, Laura, Saavedra, Portillo-Alvarez, Bustamante, Fernandez and Galvez-Nino. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Freddy Villanueva-Cotrina, freddyvillanue@gmail.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.